Clinigen Group plc Director/PDMR Shareholding (5465S)
October 03 2017 - 4:39AM
UK Regulatory
TIDMCLIN
RNS Number : 5465S
Clinigen Group plc
03 October 2017
3 October 2017
Director's Share Dealing
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company'), the
global pharmaceutical and services group, announces that it was
notified on 2 October 2017 that the following transaction took
place on 2 October 2017.
John Bacon, Non-Executive Director, sold 250,000 ordinary shares
of 0.1 pence each in the Company at a price of 1092.96 pence per
share.
Following this transaction, Mr Bacon's total beneficial interest
in the Company is 280,767 ordinary shares, representing
approximately 0.24 per cent of the current issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging
managerial responsibilities/person
closely associated
---- -------------------------------------------------------
a) Name John Bacon
---- ---------------------- -------------------------------
2 Reason for the notification
---- -------------------------------------------------------
a) Position/status Non-Executive Director
---- ---------------------- -------------------------------
b) Initial Initial Notification
notification
/Amendment
---- ---------------------- -------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- -------------------------------------------------------
a) Name Clinigen Group plc
---- ---------------------- -------------------------------
b) Legal Entity N/A
Identifier
---- ---------------------- -------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type
of instrument; (ii) each type of
transaction; (iii) each date; and
(iv) each place where transactions
have been conducted
---- -------------------------------------------------------
a) Description Ordinary shares of 0.1 pence
of the financial each
instrument, GB00B89J2419
type of
instrument
Identification
code
---- ---------------------- -------------------------------
b) Nature of Sale of shares
the transaction
---- ---------------------- -------------------------------
c) Currency GBP
---- ---------------------- -------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- ---------------------- -------------- ---------------
1092.96p 250,000
--------------------------- -------------- ---------------
e) Aggregated 250,000
information
- Aggregated 1092.96p
volume
- Price GBP2,732,400
- Aggregated
total
--------------------------- -------------------------------
f) Date of 2 October 2017
the transaction
---- ---------------------- -------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- ---------------------- -------------------------------
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283
495 010
Shaun Chilton, Group Chief
Executive Officer
Martin Abell, Group Chief Financial
Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
RBC Capital Markets - Joint Tel: +44 (0) 20
Broker 7653 4000
Marcus Jackson / Elliot Thomas
/ Jack Wood
Instinctif Partners (media Tel: +44 (0) 20
relations) 7457 2020
Melanie Toyne-Sewell / Alex
Shaw / Deborah Bell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time through three areas
of global medicine supply; clinical trial, unlicensed and licensed
medicines.
Clinical Trial Services
Clinigen is the global market leader in the specialist supply
and management of quality-assured comparator medicines and services
to clinical trials and Investigator Initiated Trials.
Unlicensed Medicines
Clinigen is the global leader in ethically sourcing and
supplying unlicensed medicines to hospital pharmacists and
physicians for patients with a high unmet medical need. The Group
manages early access programmes to innovative new medicines and
provides 'on-demand' access globally to medicines which remain
unlicensed at the point of care.
Commercial Medicines
The Group acquires global rights to niche hospital-only and
critical care products, revitalising these assets around the world
and returning them back to sustained growth. The Group also
provides access to licensed and branded generic medicines in the
Africa and Asia Pacific region.
For more information on Clinigen, please visit
www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFVAIELVIID
(END) Dow Jones Newswires
October 03, 2017 05:39 ET (09:39 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Jul 2023 to Jul 2024